Pailinrut Chinwangso

The Diversity of Isoflavone Contents and In Vitro Antioxidant Activities in Japanese Soybean (Glycine max (L.) Merr.) Cultivars

T. Anai, R. Matsumoto, Pailinrut Chinwangso, 2010 .

A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in women of childbearing age

T. Puthanakit, Yuxiao Tang, N. Bhat, 2021, Vaccine.

Antibody persistence 2 and 3 years after booster vaccination of adolescents with recombinant acellular pertussis monovalent aPgen or combined TdaPgen vaccines

P. Pitisuttithum, W. Wijagkanalan, C. Sirivichayakul, 2021, EClinicalMedicine.

Antibody persistence after vaccination of adolescents with monovalent and combined acellular pertussis vaccines containing genetically inactivated pertussis toxin: a phase 2/3 randomised, controlled, non-inferiority trial.

P. Pitisuttithum, W. Wijagkanalan, K. Boonnak, 2018, The Lancet. Infectious diseases.

Safety and immunogenicity of a combined Tetanus, Diphtheria, recombinant acellular Pertussis vaccine (TdaP) in healthy Thai adults

W. Wijagkanalan, C. Siegrist, C. Sirivichayakul, 2016, Human vaccines & immunotherapeutics.

Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam

M. Lal, J. McLellan, A. García-Sastre, 2022, Vaccine.

Boosting Teenagers With Acellular Pertussis Vaccines Containing Recombinant or Chemically Inactivated Pertussis Toxin: A Randomized Clinical Trial

W. Wijagkanalan, C. Siegrist, S. Lawpoolsri, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: Day 28 results of a phase 1/2 open-label trial

P. Pitisuttithum, J. Excler, A. Jongkaewwattana, 2023, Vaccine.

Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: Day 28 results of a phase 1/2 open-label trial

P. Pitisuttithum, J. Excler, A. Jongkaewwattana, 2023, Vaccine.

A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3, randomised controlled non-inferiority trial.

P. Pitisuttithum, K. Boonnak, K. Chokephaibulkit, 2018, The Lancet. Infectious diseases.